Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.52 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2614694 | 1.00 | HINT1 (0.55) | HINT1ADORA2AADORA2BNT5EADORA3 | |
| SCHEMBL12807374 | 1.00 | HINT1 (0.55) | HINT1ADORA2AADORA2BNT5EADORA3 | |
| SCHEMBL10162526 | 0.93 | ADORA2A (0.57) | HINT1ADORA2AADORA2BNT5EADORA3 | |
| SCHEMBL12673434 | 0.92 | HINT1 (0.55) | HINT1ADORA2AADORA2BNT5EADORA3 | |
| SCHEMBL13164319 | 0.91 | DNMT1 (0.54) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL22002019 | 0.90 | HINT1 (0.56) | HINT1ADORA2AADORA2BNT5EADORA3 | |
| SCHEMBL6829146 | 0.90 | HINT1 (0.67) | HINT1ADORA2AADORA2BNT5EADORA3 | |
| SCHEMBL24049462 | 0.87 | AHCY (0.60) | ADORA2AADORA2BNT5EADORA3ADORA1 | |
| SCHEMBL24049460 | 0.87 | AHCY (0.60) | ADORA2AADORA2BNT5EADORA3ADORA1 | |
| SCHEMBL14587512 | 0.87 | AHCY (0.60) | ADORA2AADORA2BNT5EADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143631-A1 | LIPID FORMULATION | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-05-25 | — | — | US | disclosed |
| US-8563710-B2 | Modified oligonucleotide and its preparation and application | BIOMICS BIOTECHNOLOGIES CO., LTD. (CN) | 2013-10-22 | — | — | US | disclosed |
| US-20120088815-A1 | Modified Oligonucleotide and Its Preparation and Application | BIOMICS BIOTECHNOLOGIES CO. LTD (CN) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088815-A1 | Modified Oligonucleotide and Its Preparation and Application | UNG, NSUN2, UPF1 | HINT1 843/4885ADORA2A 567/4885ADORA2B 1193/4885 |
| US-20170143631-A1 | LIPID FORMULATION | CETP, LIPA, SGMS1 | HINT1 4203/4885ADORA2A 4416/4885ADORA2B 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.